NewAmsterdam Pharma Company Stock (NASDAQ:NAMS)

Forecast Revenue Ownership Financials Chart

Previous Close

$17.02

52W Range

$8.64 - $26.35

50D Avg

$17.17

200D Avg

$19.37

Market Cap

$1.60B

Avg Vol (3M)

$294.95K

Beta

0.00

Div Yield

-

NAMS Company Profile

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

NL

Employees

57

IPO Date

Feb 09, 2021

Website

NAMS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 22
License Revenue	$97.50M

Fiscal year ends in Dec 23 | Currency in USD

NAMS Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$14.09M	$97.50M	-
Operating Income	$-182.97M	$-67.56M	$-29.83M
Net Income	-	$-148.88M	$-28.82M
EBITDA	$-182.97M	$-6.88M	$-29.81M
Basic EPS	$-2.15	$-1.83	$-0.35
Diluted EPS	$-2.15	$-1.83	$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
CGEM	Cullinan Oncology, Inc.
PRTC	PureTech Health plc
IVA	Inventiva S.A.
MRUS	Merus N.V.
MLYS	Mineralys Therapeutics, Inc.
REPL	Replimune Group, Inc.
JANX	Janux Therapeutics, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
RZLT	Rezolute, Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG
CMPX	Compass Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.